aBLA Filing Intelligence & Biosimilar Opportunity

Letybo

Letibotulinumtoxina-Wlbg

Dermatologic

IM Injection

Letybo is an injectable neurotoxin used to soften frown lines between the eyebrows by temporarily relaxing the muscles responsible. It works by blocking acetylcholine release at the neuromuscular junction, reducing muscle contractions and smoothing wrinkles.

Approval Date

29-Feb-24

Data Exclusivity Expiry

29-Feb-28

Market Exclusivity Expiry

29-Feb-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Letibotulinumtoxina-Wlbg

Innovator

HUGEL, INC.

Dosage Form

IM Injection

Strength

50 units per vial and 100 units per vial

Therapeutic Category

Dermatologic

Usage

To temporarily improve the appearance of moderate-to-severe glabellar lines

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.